Acadia Pharmaceuticals Inc(ACAD) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 27 at 4:41 PM ET (Korea 10/28 05:41)
Full metrics table
| Index | RUT | P/E | 9.08 | EPS (ttm) | 2.22 | Insider Own | 1.31% | Shs Outstand | 172.1M | Perf Week | -1.32% |
| Market Cap | 3.48B | Forward P/E | 21.5 | EPS next Y | 50.5% | Insider Trans | -2.52% | Shs Float | 170.0M | Perf Month | -1.75% |
| Enterprise Value | 2.59B | PEG | - | EPS next Q | 0.2 | Inst Own | 98.2% | Short Float | 5.35% | Perf Quarter | -23.42% |
| Income | 0.38B | P/S | 3.05 | EPS this Y | -72.9% | Inst Trans | 1.89% | Short Ratio | 4.9 | Perf Half Y | -11.03% |
| Sales | 1.14B | P/B | 2.66 | EPS next 5Y | -11.69% | ROA | 25.64% | Short Interest | 9.09M | Perf YTD | -24.49% |
| Book/sh | 7.59 | P/C | 3.63 | EPS past 3/5Y | - | ROE | 35.74% | 52W High | -34.85% ($30.96) | Perf Year | -12.27% |
| Cash/sh | 5.55 | P/FCF | 23.87 | Sales past 3/5Y | 27.48% 19.39% | ROIC | 27.85% | 52W Low | 9.68% ($18.39) | Perf 3Y | -7.31% |
| Dividend Est. | - | EV/EBITDA | 26.35 | EPS Y/Y TTM | 68.42% | Gross Margin | 91.13% | Volatility(W/M) | 2.47% 3.09% | Perf 5Y | 14.86% |
| Dividend TTM | - | EV/Sales | 2.28 | Sales Y/Y TTM | 11.75% | Oper. Margin | 7.59% | ATR (14) | 0.72 | Perf 10Y | -10.59% |
| Dividend Ex-Date | - | Quick Ratio | 3.3 | EPS Q/Q | 15.24% | Profit Margin | 33.42% | RSI (14) | 41.04 | Recom | 1.71 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.39 | Sales Q/Q | 16.4% | SMA20 | 2.04% ($19.77) | Beta | 0.88 | Target Price | $30.53 |
| Payout | - | Debt/Eq | 0.06 | Earnings | 2026/11/4 | SMA50 | -16.98% ($24.3) | Rel Volume | 0.72 | Prev Close | $19.74 |
| Employees | 798 | LT Debt/Eq | 0.05 | EPS/Sales Surpr. | 163.93% 3.85% | SMA200 | -15.15% ($23.77) | Avg Volume(3M) | 1.86M | Price | $20.17 |
| IPO | 2004/5/27 | Option/Short | Yes/Yes | Trades | 10593 | Volume | 1,329,593 | Change | 2.18% |
🧠 A commercial-stage biopharmaceutical company that sells treatments for central nervous system and rare diseases. It commercializes and sells therapies indicated for Parkinson's disease psychosis and Rett syndrome, among others, while pursuing stable, profit-based earnings and pipeline expansion. A biopharmaceutical company specializing in central nervous system and rare diseases.
Over the past 1 year, on the lower side
35% below its 1-year high.
Traded less than usual. That is 72% of its average volume.
Next earnings report: November 4
7 days to go.
ACAD makes money exceptionally well
Of every $100 in sales, $7.59 is kept as operating profit.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -72.9% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $908. Peers typically go for $1,456. Compared with its own 2-year average, it is 36% cheaper now.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Long-term returns are roughly flat
Bought 5 years ago, your return today would be +14.9%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 98.2%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #65 of 594 in the industry
Based on market cap of $3B.
TARS#63 Tarsus Pharmaceuticals Inc $3B PER - 
XENE#64 Xenon Pharmaceuticals Inc $3B PER - ACAD#65 Acadia Pharmaceuticals Inc $3B PER 9.1 
CELC#66 Celcuity Inc $3B PER - 
PBLS#67 Parabilis Medicines Inc $3B PER - 
FAQ
What kind of company is ACAD?
ACAD belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of ACAD?
The market cap of ACAD is approximately $3.5B, ranking 1,642 within its sector.
What is the P/E ratio of ACAD?
ACAD has a P/E ratio of approximately 9.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ACAD?
ACAD has recorded a 52-week high of $30.96 and a low of $18.39.
